	US 12,339,290 B2
	Phospho-tau antibodies and methods of use
Andreas Jeromin, Alachua, FL (US); and Krish Venkat, Lawrenceville, NJ (US)
Assigned to ALZPATH, INC., Carlsbad, CA (US)
Filed by ALZPATH, INC., Carlsbad, CA (US)
Filed on Jul. 11, 2024, as Appl. No. 18/770,102.
Application 18/770,102 is a continuation of application No. 18/599,751, filed on Mar. 8, 2024, granted, now 12,276,671.
Application 18/599,751 is a continuation of application No. PCT/US2022/042963, filed on Sep. 8, 2022.
Claims priority of provisional application 63/242,437, filed on Sep. 9, 2021.
Prior Publication US 2024/0360206 A1, Oct. 31, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/6896 (2013.01) [C07K 16/18 (2013.01); G01N 33/53 (2013.01); G01N 33/6857 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); G01N 2333/4704 (2013.01); G01N 2333/4709 (2013.01); G01N 2333/96416 (2013.01); G01N 2800/2821 (2013.01)]

72 Claims

1. An anti-tau antibody or antigen binding fragment thereof comprising:

a heavy chain comprising a variable heavy chain (VH) domain; and

a light chain comprising a variable light chain (VL) domain, wherein:

the VH domain comprises HCDR1 sequence comprising SEQ ID NO: 2, HCDR2 sequence comprising SEQ ID NO: 7, and HCDR3 sequence comprising SEQ ID NO: 11; and

the VL domain comprises LCDR1 sequence comprising SEQ ID NO: 15, LCDR2 sequence comprising SEQ ID NO: 21, and LCDR3 sequence comprising SEQ ID NO: 25.